Phase 1 Gout Trial, Recruiting NCT06629376 Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. Condition: Gout
Back to Gout

Phase 1 Gout Trial, Recruiting

NCT06629376
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with gout (based on 2015 international gout classification guidelines) and are not currently having a gout flare-up.
  • Your blood uric acid level is higher than 420 µmol/L (7 mg/dl) at the screening visit.
  • Your blood uric acid level has previously been measured above 420 µmol/L (7 mg/dl) on a normal diet (confirmed on more than one test, not taken twice on the same day while fasting).

Who may not be able to join:

  • You have taken medications that lower or affect uric acid levels (such as allopurinol, febuxostat, benzbromarone, or probenecid, among others) within the 14 days before joining, or you are unable to stop taking such medications during the study.
  • You have had an acute gout flare-up within the 14 days before joining the trial.
  • You have previously been treated with uric acid-breaking medications such as pegloticase or rasburicase.
  • You have a personal history of, or low enzyme activity levels related to, a condition called G6PD deficiency (a genetic enzyme disorder affecting red blood cells).
  • You have a history of, or meet the diagnostic criteria for, a condition called catalase deficiency (confirm with trial site).
  • You have been diagnosed with any type of cancer, whether or not it has been treated.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 021-52889999

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Registry
ClinicalTrials.gov
Start date
20 November 2023
Est. completion
20 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The primary outcome was safety.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov